Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
ImmuCell (Nasdaq: ICCC) reported unaudited results for the quarter ended June 30, 2026, with product sales rising 11.5% year over year to approximately $7.2 million. Gross margin declined to 33.9% from 43.7%, reflecting lower manufacturing volumes, scrap from a purchased-material quality issue, and cost shifts from the discontinued Re-Tain® program.
Net income increased to $1.8 million, or $0.20 per diluted share, versus $0.5 million, or $0.06 per basic and diluted share, aided by a one-time $2 million legal settlement from a former Re-Tain® contract manufacturer. Adjusted EBITDA grew to $2.7 million from $1.4 million. Cash and cash equivalents rose to $8.9 million, with operating cash flow of $6.6 million for the first half of 2026. The board authorized a two-phase First Defense® capacity expansion, totaling about $8.0 million ($3.5 million freeze-drying and $4.5 million colostrum processing), expected to take roughly 18 months and intended to be funded from cash on hand and cash from operations.
ImmuCell (Nasdaq: ICCC) expects to report unaudited financial results for the quarter ended June 30, 2026 after market close on August 13, 2026. The Company will host a conference call and webcast on August 14, 2026 at 9:00 AM ET to review these results and anticipates no change to previously disclosed preliminary sales figures.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited Q2 2026 product sales of $7.2 million, up 11.5% year over year, driven by a 27.7% increase in domestic sales and a 38.9% decline in international sales.
For the first six months of 2026, total product sales were $17.5 million, a 20.9% increase versus 2025, with domestic sales up 32.5%. Tri-Shield® and Dual-Force® lines both grew. A conference call to discuss full Q2 2026 results is set for August 14, 2026.
ImmuCell (Nasdaq: ICCC) reported unaudited Q1 2026 net income of $1.9 million, or $0.21 per share, on product sales of $10.4 million, up 28.4% year over year.
Gross margin reached 45.0%. Cash rose to $6.8 million, supported by $3.4 million free cash flow, higher manufacturing output, and a $2 million settlement to fund First Defense® capacity expansion.
ImmuCell (Nasdaq: ICCC) will report unaudited results for the quarter ended March 31, 2026 after market close on May 14, 2026 and plans a conference call on May 15, 2026 at 9:00 AM ET.
ImmuCell expects no change to preliminary sales disclosed April 8, 2026, and intends to file its Form 10-Q on May 14, 2026 after market close.
ImmuCell (Nasdaq: ICCC) announced two board appointments and a governance restructure effective April 15, 2026. Dr. Gilles Guillemette and Dr. Anthony DiMarco join the board; the company will move to a seven-person board with six independent directors and create a Strategy and Technology Committee.
The new committee will be chaired by Dr. Guillemette and includes members focused on manufacturing yield, capacity expansion, and innovation-driven growth of the First Defense® product line.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited Q1 2026 product sales of $10.4 million, a 28.4% increase versus Q1 2025. Domestic sales rose 35.7% to $9.7 million while Tri-Shield First Defense sales grew 38.5% to $7.9 million; international sales fell 30.2%.
The company cited seasonal demand, inventory and manufacturing actions, and ongoing backorder effects. A conference call is scheduled for May 15, 2026 at 9:00 AM ET.
ImmuCell (Nasdaq: ICCC) appointed Kathy Turner to its Board of Directors effective April 1, 2026, replacing retiring director Steven Rosgen. Turner will chair the Compensation and Stock Option Committee and join the Audit Committee.
She brings 30+ years of global commercial leadership across animal health and healthcare, including prior board service at Elanco and senior roles at IDEXX and Abbott, and will support expansion of the First Defense® product internationally.
ImmuCell (Nasdaq: ICCC) reported unaudited results for the year ended December 31, 2025 showing product sales of $27.6M, up 4.3% year-over-year, and a gross profit margin of 41.4% versus 30.0% in 2024. Net loss narrowed to $1.0M, or ($0.12) per share.
Management cited higher volumes, manufacturing efficiencies and price realization; cash was $3.8M, inventory rose to $9.267M, and net working capital was $12.967M as of December 31, 2025.
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter and year ended December 31, 2025 after market close on March 4, 2026. The company will host a conference call on March 5, 2026 at 9:00 AM ET to review results.
Dial-in numbers, replay access (code #2017737) available through March 12, 2026. ImmuCell expects no change to preliminary sales disclosed January 8, 2026 and plans to file its Form 10-K on or before March 31, 2026.